Stichting Hemato-oncologie Voor Volwassenen Nederland
Clinical trials sponsored by Stichting Hemato-oncologie Voor Volwassenen Nederland, explained in plain language.
-
Second chance: new combo aims to control CLL after relapse
Disease control Recruiting nowThis study is for people with chronic lymphocytic leukemia (CLL) whose cancer returned after their first treatment with venetoclax and an antibody. Researchers want to see if a new combination of two drugs, venetoclax and acalabrutinib, can control the disease again. About 60 adu…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo shows promise in targeted AML trial
Disease control Recruiting nowThis phase 3 study tests whether adding bleximenib (a drug that blocks a cancer-driving protein interaction) to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has specific genetic changes (KMT2A rearrangement or NPM1 muta…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 08, 2026 12:03 UTC